African-specific polymorphisms in Plasmodium falciparum serine repeat antigen 5 in Uganda and Burkina Faso clinical samples do not interfere with antibody response to BK-SE36 vaccination

BK-SE36, based on Plasmodium falciparum serine repeat antigen 5 (SERA5), is a blood-stage malaria vaccine candidate currently being evaluated in clinical trials. Phase 1 trials in Uganda and Burkina Faso have demonstrated promising safety and immunogenicity profiles. However, the genetic diversity o...

Descripción completa

Detalles Bibliográficos
Autores principales: Arisue, Nobuko, Palacpac, Nirianne Marie Q., Ntege, Edward H., Yeka, Adoke, Balikagala, Betty, Kanoi, Bernard N., Bougouma, Edith Christiane, Tiono, Alfred B., Nebie, Issa, Diarra, Amidou, Houard, Sophie, D’Alessio, Flavia, Leroy, Odile, Sirima, Sodiomon B., Egwang, Thomas G., Horii, Toshihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Cellular and Infection Microbiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802637/
https://www.ncbi.nlm.nih.gov/pubmed/36590593
http://dx.doi.org/10.3389/fcimb.2022.1058081

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802637/
https://www.ncbi.nlm.nih.gov/pubmed/36590593
http://dx.doi.org/10.3389/fcimb.2022.1058081

Ejemplares similares